Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism

Pediatrics

Volumn 126, Issue 4, 2010, Pages 656-664

  Price, Cristofer S ^a   Thompson, William W ^b   Goodson, Barbara ^a   Weintraub, Eric S ^c   Croen, Lisa A ^d   Hinrichsen, Virginia L ^f   Marcy, Michael ^g   Robertson, Anne ^a   Eriksen, Eileen ^g   Lewis, Edwin ^d   Bernal, Pilar ^e   Shay, David ^c   Davis, Robert L ^h   DeStefano, Frank ^c  

^a ABT ASSOCIATES   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d DIVISION OF RESEARCH   (United States)

^e STANFORD UNIVERSITY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h KAISER PERMANENTE   (United States)

Author keywords

Autism; Immunoglobulins; Mercury; Thimerosal; Vaccines

Indexed keywords

ETHYLMERCURY DERIVATIVE; IMMUNOGLOBULIN; THIOMERSAL; VACCINE; PRESERVATIVE;

ADOLESCENT; ARTICLE; AUTISM; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; INFANCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERINATAL PERIOD; PRENATAL EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; AUTISTIC DISORDER; CASE CONTROL STUDY; CHEMICALLY INDUCED; INFANT; NEWBORN; PREGNANCY; RISK FACTOR;

ADOLESCENT; AUTISTIC DISORDER; CASE-CONTROL STUDIES; CHILD; ETHYLMERCURY COMPOUNDS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESERVATIVES, PHARMACEUTICAL; RISK FACTORS; THIMEROSAL; VACCINES;

EID: 77957718695     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0309     Document Type: Article

References (24)

1. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics. 2001;107(5):1147-1154 (Pubitemid 32440625)
2. Goldfrank L, Flonenbaum N, Lewin N, et al. Goldfrank's Toxicologic Emergencies. 7th ed. New York, NY: McGraw-Hill; 2002
3. Joint statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (USPHS). Pediatrics. 1999;104(3 pt 1):568-569
4. Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003;112(5):1039-1048
5. Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007;357(13):1281- 1292
6. Tozzi AE, Bisiacchi P, Tarantino V, et al. Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines. Pediatrics. 2009;123(2):475-482
7. Chen RT, DeStefano F, Davis RL, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ. 2000;78(2):186-194 (Pubitemid 30151603)
8. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics. 1997;99(6):765-773
9. DeStefano F. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf. 2001;10(5):403-406
10. Price C, Robertson A, Goodson B. Thimerosal and Autism. Technical report. Vol I. Bethesda, MD: Abt Associates Inc; 2009
11. Price C, Robertson A, Goodson B. Thimerosal and Autism. Technical report. Vol II. Bethesda, MD: Abt Associates Inc; 2009
12. Rutter M, LeCouteur A, Lord C. Autism Diagnostic Interview - Revised. Los Angeles, CA: Western Psychological Services; 2003
13. Lord C, Rutter M, DiLavor PC, Risi S. Autism Diagnostic Observation Schedule. Los Angeles, CA: Western Psychological Services; 2003
14. Rutter M, Bailey A, Lord C. SCQ: The Social Communication Questionnaire. Manual. Los Angeles, CA: Western Psychological Services; 2003
15. Physicians' Desk Reference. 49th ed. Montvale, NJ: Medical Economics Data Production Co; 1995
16. Thimerosal in vaccines: an interim report to clinicians. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health. Pediatrics. 1999;104(3 pt 1):570-574
17. Physicians' Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Data Production Co; 1999
18. Kleinbaum DG, Klein M. Logistic Regression: A Self-learning Text. New York, NY: Springer-Verlag; 2002
19. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley-Interscience; 2000
20. Institute of Medicine. Immunization Safety Review: Vaccines and Autism. Washington, DC: National Academies; 2004
21. Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006; 118(1). Available at: http://www.pediatrics. org/cgi/content/full/118/1/e139
22. Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. Arch Gen Psychiatry. 2008; 65(1):19-24
23. Croen LA, Matevia M, Yoshida CK, et al. Maternal Rh D status, anti-D immune globulin exposure during pregnancy, and risk of autism spectrum disorders. Am J Obstet Gynecol. 2008;199(3):234.e1-e6
24. Miles JH, Takahashi TN. Lack of association between Rh status, Rh immune globulin in pregnancy and autism. Am J Med Genet A. 2007;143A(13):1397-1407